13G Filing: 683 Capital Partners and Galmed Pharmaceuticals Ltd (GLMD)

This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of December 6, 2017.

Item 1(a).

Name of Issuer:

Galmed Pharmaceuticals Ltd. (“Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

16 Tiomkin St., Tel Aviv 6578317, Israel

Item 2(a).

Name of Persons Filing:

The names of the persons filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:

·	683 Capital Management, LLC,

·	683 Capital Partners, LP and

·	Ari Zweiman.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The principal business address for each of the Reporting Persons is 3 Columbus Circle, Suite 2205, New York, NY 10019.

Item 2(c).

Citizenship:

683 Capital Management, LLC is a Delaware limited liability company.  683 Capital Partners, LP is a Delaware limited partnership.  Ari Zweiman is a citizen of the United States.

Item 2(d).

Title of Class of Securities:

Ordinary shares par value NIS 0.01 per share (the “Ordinary Shares”)

Item 2(e).

CUSIP Number:

M47238106